Bacil Pharma H1 FY26: Income Falls 83%, Cashflow Negative

Revenue declinedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.7%Reaction day

₹23.00

prior close

₹22.56

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%-3.0% vs market

Pharmaceuticals peers, median of 172sector-0.6%-4.1% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.0

10m

-2.8

15m

-2.8

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.7-1.6-3.0-0.6-4.1

Next day

-6.9-1.0-5.9-0.7-6.2

-11.6-2.6-9.0-1.9-9.7

-8.3-5.1-3.2-3.5-4.8

-11.1-6.1-5.0-4.3-6.8

-13.1-8.3-4.8-6.0-7.1

-15.9-6.4-9.6-2.8-13.1

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bacil Pharma H1 FY26 standalone total income fell to 18.09 lakhs from 105.74 lakhs in H1 FY25, an 83% drop. PBT dropped to 9.89 lakhs from 91.20 lakhs. Standalone operating cashflow turned negative at minus 224.89 lakhs. Consolidated new borrowings of 552.24 lakhs appeared. No revenue from operations; all income is other income (likely investments or dividends).

Likely market impact

Sharp income drop, negative operating cashflow, and fresh borrowings indicate financial stress on the company.